SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-044224
Filing Date
2023-05-31
Accepted
2023-05-31 08:09:24
Documents
3
Period of Report
2023-05-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea179551-6k_enlivexthera.htm 6-K 8842
2 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON MAY 31, 2023 ea179551ex99-1_enlivexthera.htm EX-99.1 11629
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4018
  Complete submission text file 0001213900-23-044224.txt   27388
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 23979022
SIC: 2834 Pharmaceutical Preparations